Every day, we strive to transform the lives of patients and families through high-precision cell therapy
Orca-T recipient
Clinical trial participant
Orca-T recipient
Clinical trial participant
FAQ
What is cell therapy?
Cell therapy is a type of treatment that uses cells to prevent or treat a disease. Orca Bio’s approach involves introducing cells from a healthy donor to completely replace a patient’s diseased blood and immune system.
How is Orca Bio’s approach different from a conventional allogeneic stem cell transplant?
In a conventional transplant, all cells from the donor are infused into the patient. This can include cells that benefit the patient as well as cells that could lead to serious side effects or transplant-related toxicities, like infections and graft versus host disease.
To build our donor-derived cell therapies, our high-precision platform identifies every single cell from the donor and uses only a small fraction of the cells that offer potential therapeutic benefit.
Orca Bio is currently evaluating its lead investigational high-precision cell therapy, Orca-T, in a Phase 3 clinical trial that is comparing it to a standard of care allogeneic stem cell transplant. We look forward to sharing the head-to-head results in 2025.
Is there data that shows how this approach works in patients?
To date, Orca Bio has treated more than 400 patients as part of ongoing clinical trials. To ensure transparency with the broader scientific community, we regularly present data on patient outcomes and safety. You can view the abstracts that have been presented at congresses like the American Society of Hematology (ASH) and the Tandem Meetings on our Publications page.
Can people be treated with these products?
Currently, patients can only access Orca Bio’s investigational cell therapies through clinical trials.
Key terms
Allogeneic cell therapy | A type of treatment in which cells from a healthy donor are infused into a patient to repair or replace a diseased blood and immune system. |
Conventional T-cells (Tcons) | Tcons are crucial in shaping immune response as they attack the diseased cells and help prevent relapse following treatment. However, they can trigger GvHD if left unchecked. |
Graft versus host disease (GvHD) | GvHD is a serious and potentially life-threatening condition that occurs when donor cells attack a patients healthy tissues or organs because they are seen as foreign. |
Regulatory T-cells (Tregs) | Tregs control the overactive immune response and are essential for protecting the patient, or “host”, cells from toxicities like GvHD after treatment. |
CD34+ stem cells | CD34+ stem cells are responsible for rebuilding the blood and immune system after treatment. |
T-cells | T-cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infections and diseases (like cancer). |
For more information for patients and their loved ones, we invite you to research the following sites:
